Donald R VanDevanter1, David J Pasta2, Michael W Konstan3. 1. Case Western Reserve University School of Medicine, Cleveland, OH, USA. Electronic address: drv15@case.edu. 2. ICON Clinical Research, San Francisco, CA, USA. 3. Case Western Reserve University School of Medicine, Cleveland, OH, USA; Rainbow Babies and Children's Hospital, Cleveland, OH, USA.
Abstract
BACKGROUND: Pulmonary exacerbations (PEx) are important CF clinical events. METHODS: We studied time to next PEx following intravenous (IV) antibiotic PEx treatment among Cleveland Ohio CF center patients occurring between January 2010 and September 2014. Patient demographics, clinical presentations, and treatments were modeled by Cox proportional hazards regression to identify covariates associated with time to next PEx. RESULTS: 193 patients were treated for PEx; 155 had a subsequent IV-treated PEx. Six covariates were associated with future PEx hazard: number of PEx in the prior year (hazard ratio 25.1 for ≥3 and 4.4 for 1-2 prior-year PEx versus none; P<.0001), IV treatment duration in weeks (1.2; P=.0004), percent hospital treatment (1.1; P=.0018), and chronic inhaled aminoglycosides (2.5; P<.0001), leukotriene modifiers (1.8; P=.0031), and high dose ibuprofen (0.52; P=.0006). CONCLUSIONS: Time to next PEx was profoundly associated with prior-year PEx, suggestive of high-risk PEx phenotypes that warrant recognition and further study.
BACKGROUND: Pulmonary exacerbations (PEx) are important CF clinical events. METHODS: We studied time to next PEx following intravenous (IV) antibiotic PEx treatment among Cleveland Ohio CF center patients occurring between January 2010 and September 2014. Patient demographics, clinical presentations, and treatments were modeled by Cox proportional hazards regression to identify covariates associated with time to next PEx. RESULTS: 193 patients were treated for PEx; 155 had a subsequent IV-treated PEx. Six covariates were associated with future PEx hazard: number of PEx in the prior year (hazard ratio 25.1 for ≥3 and 4.4 for 1-2 prior-year PEx versus none; P<.0001), IV treatment duration in weeks (1.2; P=.0004), percent hospital treatment (1.1; P=.0018), and chronic inhaled aminoglycosides (2.5; P<.0001), leukotriene modifiers (1.8; P=.0031), and high dose ibuprofen (0.52; P=.0006). CONCLUSIONS: Time to next PEx was profoundly associated with prior-year PEx, suggestive of high-risk PEx phenotypes that warrant recognition and further study.
Authors: Timothy D Murphy; Ran D Anbar; Lucille A Lester; Samya Z Nasr; Bruce Nickerson; Donald R VanDevanter; Andrew A Colin Journal: Pediatr Pulmonol Date: 2004-10
Authors: Michael W Konstan; Wayne J Morgan; Steven M Butler; David J Pasta; Marcia L Craib; Stefanie J Silva; Dennis C Stokes; Mary Ellen B Wohl; Jeffrey S Wagener; Warren E Regelmann; Charles A Johnson Journal: J Pediatr Date: 2007-06-22 Impact factor: 4.406
Authors: Maria T Britto; Uma R Kotagal; Richard W Hornung; Harry D Atherton; Joel Tsevat; Robert W Wilmott Journal: Chest Date: 2002-01 Impact factor: 9.410
Authors: A L Smith; C Doershuk; D Goldmann; E Gore; B Hilman; M Marks; R Moss; B Ramsey; G Redding; T Rubio; J Williams-Warren; R Wilmott; H D Wilson; R Yogev Journal: J Pediatr Date: 1999-04 Impact factor: 4.406
Authors: Kaïssa de Boer; Katherine L Vandemheen; Elizabeth Tullis; Steve Doucette; Dean Fergusson; Andreas Freitag; Nigel Paterson; Mary Jackson; M Diane Lougheed; Vijay Kumar; Shawn D Aaron Journal: Thorax Date: 2011-06-15 Impact factor: 9.139
Authors: Vin Tangpricha; Joshua Lukemire; Yuqing Chen; José Nilo G Binongo; Suzanne E Judd; Ellen S Michalski; Moon J Lee; Seth Walker; Thomas R Ziegler; Rabin Tirouvanziam; Susu M Zughaier; Supavit Chesdachai; Wendy A Hermes; James F Chmiel; Ruth E Grossmann; Amit Gaggar; Patricia M Joseph; Jessica A Alvarez Journal: Am J Clin Nutr Date: 2019-03-01 Impact factor: 7.045
Authors: Susanna A McColley; Michael W Konstan; Bonnie W Ramsey; J Stuart Elborn; Michael P Boyle; Claire E Wainwright; David Waltz; Montserrat Vera-Llonch; Gautham Marigowda; John G Jiang; Jaime L Rubin Journal: J Cyst Fibros Date: 2018-08-23 Impact factor: 5.482